Optimization of this compound led to the discovery of T. brucei NMT inhibitors with higher blood-brain barrier permeability and improved selectivity over human NMT, that showed partial efficacy in stage 2 (when the parasite invades the central nervous system) in the mouse model of trypanosomiasis [206]. Here, NMT1 is linked to trypanosomiasis.